News – Page 1172 – Endpoints News

Martin Shkreli, the obscene prankster of biotech, makes his final exit at KaloBios

9 years ago

Mylan CEO Bresch hopes to tame the mob with a 50% discount for the EpiPen

9 years ago

Booming Moderna is raising $600M while ramping up manufacturing and clinical studies

9 years ago

Protocols: The Mylan furor comes into play for California drug initiative; Adocia concedes a PhIII flop

9 years ago

A radically inexpensive, non-profit approach can transform drug R&D? Now, wait a minute…

9 years ago

Amid layoff fears, AstraZeneca stakes a ‘For Sale’ sign on US campus

9 years ago

Sofinnova Ventures ups the ante - again - as it closes in on $650M biotech fund

9 years ago

Thumbs Up/Thumbs Down: Amgen's silence is deafening; The drug pricing mob is back

9 years ago

Protocols: BeiGene signs up Medivation’s Amy Peterson as its new CMO; Acne drug developer files for $60M IPO

9 years ago

Denali grabs another megaround while inking a flurry of neurodegeneration R&D pacts

9 years ago

Novartis heralds a PhIII success for secondary progressive MS drug

9 years ago

That big new hyperparathyroidism drug from Amgen? The FDA rejected it

9 years ago

Biotech has a bad day after politicos pounce on another drug pricing scandal

9 years ago

Under the gun, Nymox sparks another rally with a new batch of follow-up BPH data

9 years ago

Meet Ike, the drug test subject that lived to be 140

9 years ago

Protocols: Cell Medica strikes a TCR research deal with University College London; UK offers early access to AbbVie's ...

9 years ago

BioRegnum: The mob is back. And what's to stop them from going after the entire biopharma industry?

9 years ago

Still in spotlight of a federal probe, Insys touts PhIII pain study as it preps an NDA

9 years ago

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

9 years ago

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

9 years ago

Protocols: Mylan’s EpiPen strategy stirs fresh outrage over price gouging; a flailing Woodford halts big bonuses

9 years ago

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib

9 years ago

Tokai retreats from the clinic after lead drug implodes in PhIII

9 years ago

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

9 years ago

First page Previous page 1169 1170 117111721173 1174 1175 Next page Last page